

## **Dr. Kester Nahen joins Preceyes as Chief Commercial Officer**

**Eindhoven, The Netherlands, September 23, 2019 - Preceyes B.V., the medical robotics company developing and commercializing the first market-cleared robot for retina surgery, announced that it has appointed Dr. Kester Nahen as its Chief Commercial Officer. Dr. Nahen is a medical device industry expert focused on ophthalmology and brings more than 18 years of well-rounded international business experience in product management and development, marketing, sales, professional education, and business development to the company.**

Previously, Dr. Nahen was with ophthalmic diagnostic device manufacturer Heidelberg Engineering GmbH for 12 years. He worked as Managing Director at the Headquarters in Germany and served on the board of Heidelberg Engineering Inc. in the US. During this time Dr. Nahen was responsible for the strategic alignment of Heidelberg's Spectralis OCT imaging platform with the arrival of innovative pharmacologic treatment for retinal diseases, fueling a strong growth phase for the company. From 2001 to 2006, Dr. Nahen worked at Laserscope Inc., a Silicon Valley based medical laser company, where he was member of the merger executive team selling Laserscope 45% over market cap at a price of \$715 million. In 2001, Dr. Nahen received his PhD in Physics from the Medical University of Lübeck, Germany.

In addition to his new function at Preceyes, Dr. Nahen will continue to serve as Chief Commercial Officer of Notal Vision, based in the Greater Washington Area, a diagnostic services company that extends eye disease management from the clinic to the patients' home.

"We are delighted to welcome Kester to the Preceyes team", said Dr. Gerrit Naus, co-founder and Chief Executive Officer of Preceyes. "Kester is an industry expert with a strong track record of successful product management, marketing and strategy in the field of ophthalmology. He brings with him a wealth of experience in commercializing and scaling medical-device businesses based on application-centered research and development. Kester's senior industry experience will be invaluable as we grow Preceyes into a leading medical device company in its field by bringing our technology to our customers and their patients."

"I am very excited to join the Preceyes team at a key inflection point for the company that is taking its robotic assistant for vitreoretinal surgery from research to clinical practice" said Dr. Nahen. "In light of recent advancements in for example gene therapy that demand precise subretinal delivery, the convergence of innovative medical device technology and advanced therapeutic solutions creates significant opportunities to drive demand for robotic assistant systems. The growing interest of pharmaceutical and device companies to partner with Preceyes indicates the value the company has created. I look forward to contribute to the commercial success of Preceyes," Dr. Nahen added.

The PRECEYES Surgical System R1.1 is the world's first market-cleared robot for retina surgery. With the recently achieved CE mark, the robotic system is now available for wider commercial deployment in Europe and can be readily integrated at major hospitals and institutes for clinical and research activities. With a surgical precision better than 20  $\mu\text{m}$ , treatment outcomes can be improved and surgeons are empowered to establish new, innovative surgical techniques, including the delivery of advanced therapeutics.

### **Further information**

Dr. Gerrit Naus, Chief Executive Officer of Preceyes B.V., +31-40-247-4789, [contact@preceyes.nl](mailto:contact@preceyes.nl). For more information on the PRECEYES Surgical System, visit [www.preceyes.nl](http://www.preceyes.nl).

**About Preceyes B.V.**

Preceyes is a medical robotics company focused on ocular surgery. The company develops, builds and commercializes innovative robotic solutions to assist eye surgeons in performing the most demanding surgical tasks. The company has a CE-marked product for its first target vitreoretinal surgery. The robot supports the surgeon in improving existing surgery and enables the development of new, high-precision treatments. Preceyes' vision is to transition eye surgery to its next evolution where robotics enables novel therapies, standardizes and improves surgical performance, and provides significant cost-saving by shifting the surgical suite to an office-based setting. [www.preceyes.nl](http://www.preceyes.nl)